S&CO Inc. Trims Position in Solventum Co. (NYSE:SOLV)

S&CO Inc. lessened its stake in shares of Solventum Co. (NYSE:SOLV) by 13.5% during the 3rd quarter, Holdings Channel reports. The fund owned 5,020 shares of the company’s stock after selling 782 shares during the quarter. S&CO Inc.’s holdings in Solventum were worth $349,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares during the last quarter. National Bank of Canada FI increased its position in shares of Solventum by 4.0% during the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock worth $314,000 after purchasing an additional 236 shares during the last quarter. IVC Wealth Advisors LLC increased its position in shares of Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after purchasing an additional 318 shares during the last quarter. Copeland Capital Management LLC acquired a new stake in shares of Solventum during the 3rd quarter worth about $26,000. Finally, Mather Group LLC. acquired a new stake in shares of Solventum during the 3rd quarter worth about $27,000.

Wall Street Analysts Forecast Growth

SOLV has been the subject of a number of recent analyst reports. Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. The Goldman Sachs Group lifted their target price on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. BTIG Research began coverage on Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. Wells Fargo & Company dropped their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. Finally, Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $68.00.

Solventum Stock Down 0.6 %

Shares of Solventum stock opened at $67.48 on Friday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The business has a 50-day simple moving average of $70.54 and a 200-day simple moving average of $62.20.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.